Thromboembolism - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 92 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Thromboembolism - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Thromboembolism - Pipeline Review, H2 2014', provides an overview of the Thromboembolism's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thromboembolism and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Thromboembolism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Thromboembolism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Thromboembolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Thromboembolism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Thromboembolism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Thromboembolism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Thromboembolism Overview 8
Therapeutics Development 9
Pipeline Products for Thromboembolism - Overview 9
Pipeline Products for Thromboembolism - Comparative Analysis 10
Thromboembolism - Therapeutics under Development by Companies 11
Thromboembolism - Therapeutics under Investigation by Universities/Institutes 13
Thromboembolism - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Thromboembolism - Products under Development by Companies 17
Thromboembolism - Products under Investigation by Universities/Institutes 18
Thromboembolism - Companies Involved in Therapeutics Development 19
AstraZeneca PLC 19
Bayer AG 20
Cereno Scientific AB 21
CSL Limited 22
Daiichi Sankyo Company, Limited 23
Gamma Therapeutics, Inc. 24
Green Cross Corporation 25
Isis Pharmaceuticals, Inc. 26
Portola Pharmaceuticals, Inc. 27
Regado Biosciences, Inc. 28
Sanofi 29
Thromboembolism - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
AZ-12971554 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
betrixaban - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
C-3 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CSL-3F7 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
edoxaban tosylate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Gammarin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
GCC-2107 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ISIS-FXIRx - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Lysimab - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Protein for Thromboembolism and Blood Coagulation - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
REG-2 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
rivaroxaban - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
semuloparin - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecules to Inhibit HDAC for Thromboembolism - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
TAP-ANV - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
YG-001 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Thromboembolism - Recent Pipeline Updates 63
Thromboembolism - Dormant Projects 80
Thromboembolism - Discontinued Products 81
Thromboembolism - Product Development Milestones 82
Featured News & Press Releases 82
Dec 08, 2014: Daiichi Sankyo Launches New Formulation of LIXIANA 60 mg Tablets (edoxaban) in Japan 82
Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 82
Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting 84
Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo's Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 84
Sep 26, 2014: Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA (edoxaban) in Japan 85
Aug 30, 2014: Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE) 85
Jun 23, 2014: Regado Biosciences REG2 Demonstrates Dose and Concentration Dependent Suppression of Thrombin Generation 86
May 28, 2014: Xarelto from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism 87
May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 88
May 12, 2014: Portola Pharmaceuticals Begins Enrollment in Phase 3 Study of FDA-Designated Breakthrough Therapy Andexanet Alfa and Factor Xa Inhibitor XARELTO 89
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 92
Disclaimer 92

List of Tables
Number of Products under Development for Thromboembolism, H2 2014 9
Number of Products under Development for Thromboembolism - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Thromboembolism - Pipeline by AstraZeneca PLC, H2 2014 19
Thromboembolism - Pipeline by Bayer AG, H2 2014 20
Thromboembolism - Pipeline by Cereno Scientific AB, H2 2014 21
Thromboembolism - Pipeline by CSL Limited, H2 2014 22
Thromboembolism - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 23
Thromboembolism - Pipeline by Gamma Therapeutics, Inc., H2 2014 24
Thromboembolism - Pipeline by Green Cross Corporation, H2 2014 25
Thromboembolism - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 26
Thromboembolism - Pipeline by Portola Pharmaceuticals, Inc., H2 2014 27
Thromboembolism - Pipeline by Regado Biosciences, Inc., H2 2014 28
Thromboembolism - Pipeline by Sanofi, H2 2014 29
Assessment by Monotherapy Products, H2 2014 30
Number of Products by Stage and Target, H2 2014 32
Number of Products by Stage and Mechanism of Action, H2 2014 34
Number of Products by Stage and Route of Administration, H2 2014 36
Number of Products by Stage and Molecule Type, H2 2014 38
Thromboembolism Therapeutics - Recent Pipeline Updates, H2 2014 63
Thromboembolism - Dormant Projects, H2 2014 80
Thromboembolism - Discontinued Products, H2 2014 81